Efficacy and safety of pharmacological and non-pharmacological therapies in Lennox-Gastaut syndrome: a systematic review and network meta-analysis

Zhengyan Zhu ^1,2 Zhenpan Zhang ^1,2 Wei Xiao ^2,3,4 Chunhua Wang ^1,2 Risheng Liang ^1,2*

• ¹ Department of Neurosurgery, Fujian Medical University Union Hospital, Fuzhou, China
• ² Fujian Institute of Neurosurgery, Fuzhou, China
• ³ Fujian Medical University Union Hospital, Fuzhou, China
• ⁴ Department of Neurosurgery, Xiangtan Central Hospital, Xiangtan, China

This study aimed to evaluate the efficacy and safety of antiepileptic drugs and non-pharmacological treatments in patients with Lennox-Gastaut syndrome (LGS).We conducted a systematic search of the PubMed, Embase, Cochrane, and Web of Science databases for randomized controlled trials (RCTs) evaluating both pharmacological and non-pharmacological interventions for LGS. The treatments assessed included cannabidiol, fenfluramine, clobazam, rufinamide, felbamate, lamotrigine, topiramate, deep brain stimulation, and anterior corpus callosotomy. The primary efficacy outcome was defined as a reduction of at least 50% in the frequency of drop seizures during treatment compared to baseline levels. The secondary efficacy outcome was measured as the median percentage reduction in monthly drop seizure frequency throughout the treatment period. Safety assessments were based on the incidence of adverse events and serious adverse events. All outcomes were ranked according to their surface under the cumulative ranking curve (SUCRA).This network meta-analysis encompassed 12 RCTs involving a total of 1,445 patients. The SUCRA indicated that clobazam 1mg/kg/day, anterior corpus callosotomy, and rufinamide were the three most effective interventions for achieving a reduction of at least 50% in drop seizures. In terms of median percentage reduction in drop seizure frequency, clobazam 1mg/kg/day ranked highest, followed by clobazam 0.5mg/kg/day and rufinamide. Regarding safety profiles, SUCRA analysis revealed that cannabidiol 20mg/kg/day had the highest likelihood of inducing adverse events, followed closely by fenfluramine 0.7mg/kg/day. Lamotrigine was found to be most likely to cause serious adverse reactions, with cannabidiol 10 mg/kg/day following closely behind.Clobazam 1mg/kg/day, anterior corpus callosotomy, and rufinamide manifested the most optimal efficacy in seizure control among LGS patients. Caution should be exercised when administering cannabidiol, lamotrigine, and fenfluramine 0.7mg/kg/day in clinical practice to mitigate safety concerns associated with drug-related side effects.